FDA Priority Review of DCCR for PWS: Latest Update and What It Means
On October 8, 2024, Soleno Therapeutics provided a regulatory update on DCCR (Diazoxide Choline Controlled-Release) tablets, which are currently undergoing priority review by the FDA as a potential treatment for hyperphagia in individuals with Prader-Willi syndrome (PWS). Although the FDA has moved forward with priority review, it has chosen not to hold an advisory committee meeting at this time. We have...
Spreading Joy: Operation Holiday Cheer Returns to Support PWS Families in 2024
Thanks to the incredible generosity of an anonymous donor, PWSA | USA is thrilled to bring back Operation Holiday Cheer for 2024! This heartwarming initiative helps spread joy to families in need by easing the financial burden of the holiday season. Through this program, a select number of families affected by Prader-Willi syndrome will receive...
PWSA | USA’s Podcast has a New Name!
As part of our ongoing efforts to best serve the Prader-Willi syndrome community, we are introducing a new name for our podcast. Moving forward, PWSA | USA’s podcast will be known as PWS United! This change is based on valuable feedback we’ve received from the community. Some members are sharing there is occasional confusion between...
FDA Accepts Application for New Drug DCCR, Moves to Priority Review
Exciting news for the Prader-Willi syndrome (PWS) community! Soleno Therapeutics has announced that the FDA has accepted their new drug application (NDA) for DCCR, a drug designed to treat hyperphagia in individuals with PWS aged 4 and older. This acceptance is a major first step, and the FDA has granted Priority Review, recognizing the potential...